{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:48:46Z","timestamp":1792986526042,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ctrv.2020.101993","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T16:50:15Z","timestamp":1582217415000},"page":"101993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Evolving role of regorafenib for the treatment of advanced cancers"],"prefix":"10.1016","volume":"86","author":[{"given":"Axel","family":"Grothey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":false,"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.101993_b0005","unstructured":"Bayer Healthcare Pharmaceuticals Inc. Regorafenib (Stivarga). U.S Food and Drug Administration Prescribing Information; 2019."},{"key":"10.1016\/j.ctrv.2020.101993_b0010","unstructured":"Bayer AG. Regorafenib (Stivarga). Summary of product characteristics. European Medicines Agency; 2018."},{"key":"10.1016\/j.ctrv.2020.101993_b0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.101993_b0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.101993_b0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.101993_b0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0040","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","article-title":"Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model","volume":"12","author":"Abou-Elkacem","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2020.101993_b0045","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ijc.28669","article-title":"Regorafenib (BAY 73\u20134506): antitumor and antimetastatic activities in preclinical models of colorectal cancer","volume":"135","author":"Schmieder","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0050","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/cam4.883","article-title":"Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models","volume":"5","author":"Zopf","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2020.101993_b0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12094-015-1373-0","article-title":"Tumor-associated macrophages in cancers","volume":"18","author":"Hu","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2017.75.1610","article-title":"Emerging targeted and immune-based therapies in sarcoma","volume":"36","author":"Pollack","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0070","doi-asserted-by":"crossref","first-page":"107096","DOI":"10.18632\/oncotarget.22334","article-title":"Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma","volume":"8","author":"Kissel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2020.101993_b0075","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.2011.39.9394","article-title":"Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial","volume":"30","author":"George","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0080","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0085","unstructured":"National Comprehensive Cancer Network Inc. Clinical practice guidelines in oncology (NCCN Guidelines): Colon Cancer. Version 1.2020-December 19, 2019; 2018."},{"key":"10.1016\/j.ctrv.2020.101993_b0090","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","article-title":"Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations","volume":"33","author":"Yoshino","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2020.101993_b0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1634\/theoncologist.2018-0072","article-title":"Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study","volume":"24","author":"Van Cutsem","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2020.101993_b0100","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12885-016-2440-9","article-title":"Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program","volume":"16","author":"Adenis","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2019.09.015","article-title":"Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study","volume":"123","author":"Ducreux","year":"2019","journal-title":"Eur J Cancer"},{"issue":"Suppl. 4S","key":"10.1016\/j.ctrv.2020.101993_b0110","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.2018.36.4_suppl.748","article-title":"Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study","volume":"36","author":"Schulz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0115","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1634\/theoncologist.2018-0377","article-title":"Large-scale, prospective observational study of regorafenib in Japanese patients with metastatic colorectal cancer in a real-world clinical setting","volume":"24","author":"Yamaguchi","year":"2019","journal-title":"Oncologist"},{"issue":"Suppl. 6","key":"10.1016\/j.ctrv.2020.101993_b0120","first-page":"516P","article-title":"Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial","volume":"27","author":"Grothey","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl. 6","key":"10.1016\/j.ctrv.2020.101993_b0125","first-page":"506P","article-title":"Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)","volume":"27","author":"Garcia-Carbonero","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ctrv.2020.101993_b0130","first-page":"P-295","article-title":"Subgroup analysis by progression-free survival (PFS) of Asian patients treated with regorafenib in the phase 3 CONCUR trial","volume":"28","author":"Kim","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0135","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv235.10","article-title":"Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC)","volume":"26","author":"Grothey","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0140","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1634\/theoncologist.2019-0067","article-title":"Regorafenib in patients with antiangiogenic-naive and chemotherapy-refractory advanced colorectal cancer: results from a phase 2b trial","volume":"24","author":"Riechelmann","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2020.101993_b0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdy526","article-title":"REVERCE: A randomized phase II Study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients","volume":"30","author":"Shitara","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0150","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Suppl. 4S","key":"10.1016\/j.ctrv.2020.101993_b0155","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1200\/JCO.2018.36.4_suppl.821","article-title":"Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy","volume":"36","author":"Kudo","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.ctrv.2020.101993_b0160","article-title":"Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)","volume":"30","author":"Argiles","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0165","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ejca.2015.02.013","article-title":"Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial","volume":"51","author":"Argiles","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0170","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1002\/cncr.31552","article-title":"Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer","volume":"124","author":"Sanoff","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdy038","article-title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","volume":"29","author":"Arnold","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0180","first-page":"e117","article-title":"Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice","volume":"18","author":"Bekaii-Saab","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"Suppl","key":"10.1016\/j.ctrv.2020.101993_b0185","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2019.37.15_suppl.2522","article-title":"Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)","volume":"37","author":"Fukuoka","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0190","unstructured":"National Comprehensive Cancer Network Inc. Clinical practice guidelines in oncology (NCCN Guidelines): soft tissue sarcoma. Version 4.2019-September 12, 2019; 2018."},{"issue":"Suppl_4","key":"10.1016\/j.ctrv.2020.101993_b0195","doi-asserted-by":"crossref","first-page":"iv68","DOI":"10.1093\/annonc\/mdy095","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0200","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0205","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdw228","article-title":"Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy","volume":"27","author":"Ben-Ami","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0210","unstructured":"ClinicalTrials.gov. A randomised trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST) (ALT GIST). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02365441 [accessed 12 February 2020]."},{"key":"10.1016\/j.ctrv.2020.101993_b0215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fonc.2018.00135","article-title":"Advances and challenges on management of gastrointestinal stromal tumors","volume":"8","author":"Mei","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0220","unstructured":"FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation [accessed 12 February 2020]."},{"key":"10.1016\/j.ctrv.2020.101993_b0225","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2020.101993_b0235","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0240","unstructured":"Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, et al. Updated overall survival analysis and further exploratory analyses from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment. In: Presented at the International Liver Cancer Association (ILCA) 11th annual conference. Seoul, South Korea; 2017 [Abstract O-031]."},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2020.101993_b0245","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2017.35.4_suppl.344","article-title":"Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial","volume":"35","author":"Finn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0250","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2020.101993_b0255","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2020.101993_b0260","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","article-title":"Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma","volume":"156","author":"Teufel","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2020.101993_b0265","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","article-title":"Insights into the success and failure of systemic therapy for hepatocellular carcinoma","volume":"16","author":"Bruix","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2020.101993_b0270","author":"Cheng","year":"2019","journal-title":"Asia"},{"key":"10.1016\/j.ctrv.2020.101993_b0275","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/1878-0261.12194","article-title":"FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro","volume":"12","author":"Cha","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0280","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13046-015-0243-5","article-title":"Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer","volume":"34","author":"Huynh","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.101993_b0285","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2015.65.1901","article-title":"Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial","volume":"34","author":"Pavlakis","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl. 15","key":"10.1016\/j.ctrv.2020.101993_b0290","doi-asserted-by":"crossref","first-page":"TPS4136","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4136","article-title":"Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)\u2014An international study organized by the Australasian Gastrointestinal Trials Group (AGITG)","volume":"35","author":"Sjoquist","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.ctrv.2020.101993_b0295","article-title":"Beyond first line treatment for advanced esophagogastric adenocarcinoma (EGAC): A phase 1 dose escalation study of regorafenib (Reg) combined with paclitaxel (PTX) (REPEAT study)","volume":"28","author":"Schokker","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0300","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1634\/theoncologist.2019-0492","article-title":"Regorafenib in combination with first-line chemotherapy for metastatic esophagogastric cancer","volume":"25","author":"Moy","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2020.101993_b0305","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.15133.1","article-title":"Recent advances in the management of gastric adenocarcinoma patients","volume":"7","author":"Harada","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.ctrv.2020.101993_b0310","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.3748\/wjg.v25.i38.5773","article-title":"Targeted therapies in metastatic gastric cancer: current knowledge and future perspectives","volume":"25","author":"Pellino","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2020.101993_b0315","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cncr.22455","article-title":"Markers of angiogenesis and clinical features in patients with sarcoma","volume":"109","author":"DuBois","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0320","first-page":"iv51-67","article-title":"Soft tissue and visceral sarcomas: ESMO\u2013EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0325","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0330","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S1470-2045(16)30509-5","article-title":"Regorafenib: efficacy in multiple refractory sarcoma types","volume":"17","author":"Healey","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0335","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2018.05.008","article-title":"Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma","volume":"99","author":"Brodowicz","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0340","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1200\/JCO.2018.36.15_suppl.11505","article-title":"A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced\/metastatic, treatment-refractory liposarcoma: results from the SARC024 study","volume":"36","author":"Riedel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.ctrv.2020.101993_b0345","doi-asserted-by":"crossref","first-page":"11005","DOI":"10.1200\/JCO.2017.35.15_suppl.11005","article-title":"A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results","volume":"35","author":"Attia","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0350","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0355","unstructured":"ClinicalTrials.gov. A phase II study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas (REGOBONE) [NCT02389244]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02389244 [accessed 12 February 2020]."},{"key":"10.1016\/j.ctrv.2020.101993_b0360","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0365","first-page":"iv79-iv95","article-title":"sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.33590\/emjoncol\/10310137","article-title":"Recent advances in the treatment of metastatic soft tissue sarcoma","volume":"6","author":"Davis","year":"2018","journal-title":"EMJ Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0375","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0380","doi-asserted-by":"crossref","first-page":"113444","DOI":"10.18632\/oncotarget.23049","article-title":"Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients","volume":"8","author":"Yeh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2020.101993_b0385","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1200\/JCO.2018.36.15_suppl.4082","article-title":"Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers","volume":"36","author":"Kim","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0390","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2019","journal-title":"Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2020.101993_b0395","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2019.37.4_suppl.345","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: a randomized double-blinded placebo-controlled phase II trial","volume":"37","author":"Demols","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl. 4S","key":"10.1016\/j.ctrv.2020.101993_b0400","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2018.36.4_suppl.427","article-title":"A multicenter phase Ib-IIR trial assessing activity of regorafenib in combination with modified gemcitabine-oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC)","volume":"36","author":"Assenat","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0405","unstructured":"National Comprehensive Cancer Network Inc. Clinical practice guidelines in oncology (NCCN guidelines): hepatobiliary cancers. Version 4.2019-December 20, 2019; 2018."},{"key":"10.1016\/j.ctrv.2020.101993_b0410","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0415","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/CMAR.S157156","article-title":"Biliary tract cancer: current challenges and future prospects","volume":"11","author":"Ghidini","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ctrv.2020.101993_b0420","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11864-014-0308-2","article-title":"Current role of anti-angiogenic strategies for glioblastoma","volume":"15","author":"Thomas","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0425","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3892\/ol.2016.4952","article-title":"Glioblastoma multiforme: effect of hypoxia and hypoxia inducible factors on therapeutic approaches","volume":"12","author":"Huang","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2020.101993_b0430","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0435","unstructured":"ClinicalTrials.gov. A trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma (GBM AGILE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03970447 [accessed 12 February 2020]."},{"key":"10.1016\/j.ctrv.2020.101993_b0440","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fonc.2018.00419","article-title":"A critical overview of targeted therapies for glioblastoma","volume":"8","author":"Jain","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0445","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0450","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0455","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3816\/CGC.2009.n.002","article-title":"Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis","volume":"7","author":"Chu","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0460","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jjco\/hyt054","article-title":"Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial","volume":"43","author":"Ueda","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0465","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0470","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1743-7563.2012.01525.x","article-title":"Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience","volume":"8","author":"Zhou","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0475","doi-asserted-by":"crossref","first-page":"905-12","DOI":"10.1007\/s10147-015-0790-y","article-title":"Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial","volume":"20","author":"Komatsu","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0480","first-page":"557","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0485","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.critrevonc.2017.09.016","article-title":"Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis","volume":"119","author":"Li","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2020.101993_b0490","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2020.101993_b0495","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.15088","article-title":"Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib","volume":"49","author":"D\u00edaz-Gonz\u00e1lez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2020.101993_b0500","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2014.03.030","article-title":"Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib","volume":"61","author":"Reig","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2020.101993_b0505","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0510","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s10637-013-9977-0","article-title":"Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis","volume":"31","author":"Belum","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2020.101993_b0515","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1634\/theoncologist.2013-0059","article-title":"Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care","volume":"19","author":"Grothey","year":"2014","journal-title":"Oncologist"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2020.101993_b0520","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1200\/JCO.2017.35.15_suppl.3551","article-title":"Hand-foot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC)","volume":"35","author":"Grothey","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl. 4S","key":"10.1016\/j.ctrv.2020.101993_b0525","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2018.36.4_suppl.412","article-title":"Hand\u2013foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib","volume":"36","author":"Bruix","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0530","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.29515","article-title":"Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events","volume":"67","author":"Rimola","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2020.101993_b0535","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1136\/gutjnl-2017-314178","article-title":"Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study","volume":"67","author":"Khan","year":"2018","journal-title":"Gut"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2020.101993_b0540","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1200\/jco.2013.31.15_suppl.3637","article-title":"Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study","volume":"31","author":"Grothey","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0545","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1634\/theoncologist.2019-0033","article-title":"Phase II trial of continuous regorafenib dosing in patients with gastrointestinal stromal tumors after failure of imatinib and sunitinib","volume":"24","author":"Kim","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2020.101993_b0550","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.101993_b0555","first-page":"274","article-title":"Optimizing treatment sequence for late-line metastatic colorectal cancer patients using trifluridine\/tipiracil and regorafenib","volume":"17","author":"Unseld","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0560","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2017.02.032","article-title":"Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them","volume":"66","author":"Bruix","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2020.101993_b0565","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2020.101993_b0570","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0590","first-page":"377","article-title":"Predictive value of early tumor shrinkage and density reduction of lung metastases in patients with metastatic colorectal cancer treated with regorafenib","volume":"16","author":"Vanwynsberghe","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ctrv.2020.101993_b0595","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00259-016-3577-0","article-title":"Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib","volume":"44","author":"Lim","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2020.101993_b0600","doi-asserted-by":"crossref","first-page":"e000111","DOI":"10.1136\/esmoopen-2016-000111","article-title":"Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)","volume":"1","author":"Ricotta","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2020.101993_b0575","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0605","doi-asserted-by":"crossref","first-page":"101912","DOI":"10.1016\/j.ctrv.2019.101912","article-title":"Molecular insight of regorafenib treatment for colorectal cancer","volume":"81","author":"Arai","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2020.101993_b0610","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/annonc\/mdw388.28","article-title":"Mart\u00ednez V. Phase II, single-arm, nonrandomized, and multicenter clinical trial of regorafenib (REG) as a single agent in the first line setting for patients with metastatic and\/or unresectable KIT\/PDGFR wild-type GIST. A GEIS and ISG study","volume":"27","author":"Broto","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0615","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0620","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","article-title":"Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure)","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0625","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s12885-019-5753-7","article-title":"First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","volume":"19","author":"Carrato","year":"2019","journal-title":"BMC Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2020.101993_b0630","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/jco.2016.34.4_suppl.156","article-title":"Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST)","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.101993_b0635","doi-asserted-by":"crossref","first-page":"44121","DOI":"10.18632\/oncotarget.17310","article-title":"A phase II trial of regorafenib in patients with metastatic and\/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17","volume":"8","author":"Yeh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2020.101993_b0640","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study","volume":"49","author":"Bruix","year":"2013","journal-title":"Eur J Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2020.101993_b0645","article-title":"(BREGO) Regorafenib combined with modified (m) GEMOX (Gemcitabine- Oxaliplatin) in patients with advanced biliary tract cancer (BTC): a phase Ib\/II randomized trial","volume":"26","author":"Assenat","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:22:01Z","timestamp":1759656121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":127,"alternative-id":["S0305737220300311"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.101993","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving role of regorafenib for the treatment of advanced cancers","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.101993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101993"}}